Lv33
374 积分 2024-03-22 加入
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
13天前
已完结
Catalytic Enantioselective Chlorofunctionalizations of N-Substituted Amides Using In Situ Generated HOCl as Hydrogen Bond Source
14天前
已完结
Design, synthesis and evaluation of pterostilbene-indole hybrids as potential anticancer agents
15天前
已完结
FGFR-1 in complex with ligand lenvatinib
17天前
已关闭
Crystal structure of human PDGFRA
17天前
已关闭
The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
17天前
已完结
Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
19天前
已完结
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
19天前
已完结
A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance
19天前
已完结
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma
19天前
已完结
皖公网安备34019202002308
